Get started Log in

FBIO — Fortress Biotech Share News

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Market Cap
$64.37m
Enterprise Value
-$50.66m
Revenue
$63.26m

U.S. RESEARCH ROUNDUP-Intuit, Rent the Runway, Tesla
11/09/2023 08:21
Brief: Journey Medical Corporation Enters Into An Exclusive License Agreement With Maruho Co., Ltd. For Qbrexza® In South Korea And Other Asian Nations
06/09/2023 16:17
Brief: Mustang Bio Announces First Data From Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating Mb-106 Car-T Cell Therapy
16/08/2023 13:04
Fortress Biotech Inc reports results for the quarter ended in June - Earnings Summary
16/08/2023 03:57
Fortress Biotech Inc expected to post a loss of 23 cents a share - Earnings Preview
12/08/2023 03:02
Fortress Biotech Inc expected to post a loss of 23 cents a share - Earnings Preview
09/08/2023 21:07
Fortress Biotech Inc expected to post a loss of 23 cents a share - Earnings Preview
04/08/2023 12:10
Brief: Mustang Bio Announces Amendment And Closing Of Partnership With uBriGene Biosciences
31/07/2023 13:44
Brief: Avenue Therapeutics Says First Patient Dosed In Phase 1B/2A Trial Of AJ201
27/07/2023 15:06
Brief: Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases In Complete Response Rates In Advanced Cutaneous Squamous Cell Carcinoma
27/07/2023 12:09
Brief: Avenue Therapeutics Announces Agreement With The FDA On Phase 3 Study Design For IV Tramadol
25/07/2023 13:36
Brief: Journey Medical Corporation Expects Topline Results FromPhase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 For The Treatment Of Papulopustular Rosacea To Be Announced Week Of July 10
03/07/2023 13:12
Brief: Urica Therapeutics Announces Topline Data From The Phase 1 Clinical Trial Evaluating Dotinurad
29/06/2023 14:32
Brief: Mustang Bio Announces Final Results From Follicular Lymphoma Cohort Of Single-Institution Phase 1/2 Clinical Trial Of MB-106
15/06/2023 21:07
Brief: Journey Medical Corp Announces Topline Data From Phase 1 Clinical Trial Of DFD-29
13/06/2023 15:12
Brief: Mustang Bio - MB-106 Continues To Demonstrate Favorable Safety, Efficacy Profile
12/06/2023 14:32
Brief: Checkpoint Therapeutics Announces $10 Mln Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
23/05/2023 14:26
Brief: Journey Medical Reports Q1 Loss Of $0.57 Per Share
22/05/2023 22:48
Brief: Mustang Bio Announces Strategic Manufacturing Partnership And Portfolio Updates
18/05/2023 13:10
Fortress Biotech Inc reports results for the quarter ended in March - Earnings Summary
16/05/2023 19:20